Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer

Publisher： Karger

E-ISSN： 1421-9794|56|2|94-100

ISSN： 0009-3157

Source： Chemotherapy, Vol.56, Iss.2, 2010-03, pp. : 94-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 1-7

Karger

Access to resources Recommend Favorite

Prospective Phase II Trial of Gemcitabine in Combination with Irinotecan as First-Line Chemotherapy in Patients with Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 57, Iss. 3, 2011-05 ,pp. : 236-243

Karger

Access to resources Recommend Favorite

A Phase II Trial of Epirubicin, Oxaliplatin, and Capecitabine (EOX) as First-Line Chemotherapy in Advanced Gastric Cancer: A Chinese Single-Center Experience

By  

Chemotherapy, Vol. 56, Iss. 3, 2010-04 ,pp. : 171-177

Karger

Access to resources Recommend Favorite

A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

By  

Chemotherapy, Vol. 58, Iss. 5, 2013-01 ,pp. : 411-418

Karger

Access to resources Recommend Favorite

Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer

By  

Chemotherapy, Vol. 61, Iss. 4, 2016-02 ,pp. : 197-203

Karger

Access to resources Recommend Favorite